版本:
中国

BRIEF-Benitec Biopharma says key pre-clinical data on muscular dystrophy published in nature communications

April 4 Benitec Biopharma Ltd:

* Benitec Biopharma Ltd - key pre-clinical data on oculopharyngeal muscular dystrophy (opmd) published in nature communications

* Benitec Biopharma Ltd - data from studies show ddrnai approach to 'silence and replace' mutant pabpn1 protein, results in correction of muscular dystrophy

* Benitec Biopharma - data from studies show ddrnai approach to 'silence and replace' mutant pabpn1 protein, results in correction of key clinical features of opmd

* Benitec Biopharma Ltd - bb-301 is currently in preclinical development and benitec plans to initiate ind-enabling studies later this year Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐